Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell Leukaemia

Prior treatment

• No previous treatments, except for induction therapy for primary plasma cell leukemia.
• Administration of any anti-BCMA therapy as part of induction
• Active immunosuppressive therapy except for prednisone 10 mg/day (or equivalent).
• Any other concomitant neoplasia, unless it has been in complete remission for 3 years or longer, except for non-melanoma skin cancer or completely resected in situ carcinoma.
• Previous diagnosis of symptomatic AL amyloidosis,
• Women of childbearing potential, including those whose last menstrual cycle was in the year prior to screening, who are unable or unwilling to use highly effective contraceptive methods\* from the beginning of the study to completion of the study.
• Contraindication to receive lymphodepletive chemotherapy.

Other illness

• Active infection requiring treatment.
• Active HIV, HBV, or HCV infection.
• Uncontrolled medical illness

Lab values

• Absolute lymphocyte count \<0.1x109/L
• Severe organ impairment that meets any of the following criteria: EF\<40%, DLCO \<40%, GFR \<30 ml/min, bilirubin \>3 times the upper limit of normality (unless due to Gilbert syndrome)

Other

• Not having achieved at least a minimal response with induction treatment (IMWG criteria)
• Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test at the screening phase.
• Men who are unable or unwilling to use highly effective contraceptive methods\* from the beginning of the study to completion of the study.

• Patients between 18 and 75 years old diagnosed with newly diagnosed primary plasma cell leukemia (the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma), according to International Myeloma Working Group (IMWG).
• Disease measurable at diagnosis by monoclonal component in serum or urine, or by free light chains in serum according to the eligibility criteria for clinical trials of the "International Myeloma Working Group".
• ECOG Performance Status from 0 to 2
• Life expectancy greater than 3 months.
• Adequate venous access and absence of contraindications for lymphoapheresis.
• Patients who, after being informed, give their consent by signing the Informed Consent Document.
• Up to two cycles of previous treatment for symptomatic control will be allowed before inclusion.